Caroline Baumal - 03 Jan 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Chief Medical Officer
Signature: /s/ David Watson, attorney-in-fact for Caroline Baumal
Issuer symbol: APLS
Transactions as of: 03 Jan 2023
Net transactions value: +$2,463,720
Form type: 4
Filing time: 05 Jan 2023, 18:57:59 UTC
Next filing: 05 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Award	$0	+35,549	+26654%	$0.000000	35,682	03 Jan 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Award	$2,463,720	+49,000		$50.28	49,000	03 Jan 2023	Common Stock	49,000	$50.28	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This represents a Restricted Stock Unit award granted on 01/03/2023 that vest 25% annually over four years from grant date subject to continued service.
F2	This represents a stock option was granted on 01/03/2023 and has a four year vesting period. 25% vest one year from grant and then monthly thereafter subject to continued service.